Aktis Oncology, Inc. (AKTS) Stock: Price, Forecast & Analyst Target
Aktis Oncology, Inc. (AKTS) — MoonshotScore 26/100 (Weak band), calculated Oct 26, 2026. Price $15.73 (0.00%), as of the Oct 26, 2026 trading session; market cap $845M.
Educational signal · not a buy or sell recommendation · How to read this
Aktis Oncology, Inc. · AKTS · NASDAQ
Aktis Oncology, Inc. is a clinical-stage oncology company focused on developing targeted radiopharmaceutical therapies for cancer treatment. Their miniprotein radioconjugate platform aims to deliver tumor-killing radioisotopes with precision.
Price as of Oct 26, 2026
Key Statistics
MoonshotScore v2 · Aktis Oncology (AKTS)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strong balance sheet, but weak quality and stalling growth. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $3M (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 2 of 8
- Altman Z 7.07 · Piotroski F 2
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 25 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak | |
| 26 | Weak |
The score was 26 in the stored Oct 24, 2026 snapshot and remains 26 in the current publication computed Oct 26, 2026 (0).
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $15.73 | |
| Change on the day | 0.00% | |
| 52-week range | $14.72 – $34.19 | |
| Market capitalisation | $845M | |
| Price / earnings (trailing) | -12.17 | |
| Shares traded on the day | 150.0K |
Price & events
Other perspectives
Council score for Aktis Oncology (AKTS): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the AKTS film — every key number, told as a short cinematic story
~2 min · open the film
What is Aktis Oncology (AKTS), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Aktis Oncology, Inc. (AKTS) is listed on NASDAQ. It employs 79 people and is led by Matthew Roden. In Q2 FY2026 it reported revenue of $3M and net income of -$24M. The market values it at $845M.
What do the latest results show for Aktis Oncology (AKTS)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $3M. Against analyst estimates the company has EPS beat 2 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $3M | -$24M | -$0.44 (diluted) |
| Q1 FY2026 | $3M | -$18M | -$0.33 (diluted) |
| Q4 FY2025 | $2M | -$15M | -$0.28 (diluted) |
| Q3 FY2025 | $2M | -$16M | $0.00 (diluted) |
What are the financial strengths and risks for Aktis Oncology (AKTS)?
Short answer
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z 7.07 · Piotroski F 2. Trailing ratios: ROE -41.1% · ROA -13.1% · current ratio 16.33 · earnings yield -8.0% · free-cash-flow yield -9.6%.
Data-derived red flags
- Negative return on equity (-41.1%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Aktis Oncology (AKTS)?
Short answer · as of
Current published price targets run low $35.00 · high $40.00 · consensus $37.40 · median $37.00 against a quoted price of $15.73 (as of Oct 26, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Aktis Oncology compare with its peers?
Short answer
Aktis Oncology's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $1279.14 Oct 26, 2026 | $1.20T | 98 5-pillar Oct 26, 2026 | |
| $50.17 Oct 26, 2026 | $1.43B | 96 5-pillar Oct 26, 2026 | |
| $7.94 Oct 26, 2026 | $612M | 95 5-pillar Oct 26, 2026 | |
| $49.91 Oct 26, 2026 | $926M | 93 5-pillar Oct 26, 2026 | |
| $9.53 Oct 26, 2026 | $566M | 91 5-pillar Oct 26, 2026 | |
| $3.85 Oct 26, 2026 | $570M | 88 5-pillar Oct 26, 2026 | |
| $153.81 Oct 26, 2026 | $292B | 86 5-pillar Oct 26, 2026 | |
| $4.20 Oct 26, 2026 | $832M | 85 5-pillar Oct 26, 2026 | |
| $11.90 Oct 26, 2026 | $793M | 79 5-pillar Oct 26, 2026 | |
| $8.81 Oct 26, 2026 | $506M | 67 5-pillar Oct 26, 2026 | |
| $55.75 Oct 26, 2026 | $10.8B | 66 5-pillar Oct 26, 2026 | |
| $8.96 Oct 26, 2026 | $928M | 66 5-pillar Oct 26, 2026 | |
| Aktis Oncology (AKTS) — this page | $15.73 | $845M | 26 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $35.00 – $40.00
- Consensus target
- $37.40
- Median target
- $37.00
Consensus record · Captured .
Measured against a quoted price of $15.73 (as of Oct 26, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 23, 2026
- Transactions
- 4
- Identified insiders
- 1
- Purchases
- 0
- Sales
- 2
- Other transactions
- 2
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Aktis Oncology (AKTS)?
- Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
- Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
What Investors Ask About Aktis Oncology (AKTS)
These answers are editorial: 1 of these 9 answers is drawn from the AKTS research dossier (written May 4, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AKTS?
AKTS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Aktis Oncology, Inc. is a clinical-stage oncology company focused on developing targeted radiopharmaceutical therapies for cancer treatment.
Is AKTS a good stock to buy?
Stock Expert AI does not rate AKTS buy, sell or hold. Aktis Oncology, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AKTS stock price today?
The last price recorded on this page for Aktis Oncology, Inc. (AKTS) is $15.73, as of the Oct 26, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AKTS price target?
The analyst consensus price target for Aktis Oncology, Inc. (AKTS) is $37.40 (range $35.00 to $40.00, median $37.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about AKTS stock?
Analyst coverage of Aktis Oncology is still emerging, given its stage of development. Current sentiment reflects cautious optimism regarding the potential of its radiopharmaceutical platform and lead candidates. Key valuation metrics are difficult to assess due to the lack of current revenue and profitability.
What are the key factors to evaluate for AKTS?
Aktis Oncology, Inc. (AKTS) holds a MoonshotScore in the low range. Analysts target $37.40 (+138%). This platform innovation can create a pipeline of novel therapies, driving long-term growth. Not financial advice.
How frequently does AKTS data refresh on this page?
AKTS's price is the last quote we recorded, from the Oct 26, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AKTS's recent stock price performance?
Aktis Oncology, Inc. (AKTS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative miniprotein radioconjugate platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AKTS overvalued or undervalued right now?
Aktis Oncology, Inc. (AKTS) is loss-making, so its trailing P/E is negative (-12.17x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $37.40 (+138%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 4, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (22 figures)
The 22 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 14 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $15.73 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T23:24:23.075Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $845M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-26. FMP quote timestamp: 2026-10-26T20:00:01.000Z. Captured from FMP at 2026-10-26T23:24:20.970Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $3M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -12.17 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 150.0K | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$24M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $35.00 · high $40.00 · consensus $37.40 · median $37.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $35.00 – $40.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $37.40 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $37.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 4 transactions · 0 purchases, 2 sales, 2 other transactions · 1 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 23, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-18 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 7.07 · Piotroski F 2 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-25 · Expired observation | |
px.range52 | 52-week range | $14.72 – $34.19 | UNRECORDED | Stored company-profile observation — Captured 2026-10-25 | |
id.employees | Employees | 79 | UNRECORDED | Stored company-profile observation — Captured 2026-10-25 | |
id.ceo | Chief executive | Matthew Roden | UNRECORDED | Stored company-profile observation — Captured 2026-10-25 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -41.1% · ROA -13.1% · current ratio 16.33 · earnings yield -8.0% · free-cash-flow yield -9.6% | — | UNRECORDED | Stored key metrics — Date unknown |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 26 of 100 · Weak · pillars 27 / 83 / 49 / 17 / 35 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 26 (stored snapshot Oct 24, 2026) → 26 (current publication computed Oct 26, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.